Assessment of TRACP-5b in Primary and Secondary Osteoporosis
Study Details
Study Description
Brief Summary
Assessment of the TRACP-5b level in 1ry OP and 2ry OP such as RA and seronegative spondylitis, that may help in surrogating the use of BMD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Osteoporosis is a disease characterized by low bone density and a deterioration of bone microarchitecture that reduces bone strength and increases the risk of fracture. The hallmark of osteoporosis is the loss of both bone mineral and bone matrix. Although Bone mass density (BMD) is still the gold standard for the diagnosis of osteoporosis, but bone turnover markers (BTMs) can provide helpful information regarding the bone remodelling process. One of these relatively recent markers is the Tartrate-resistant acid phosphatase (TRACP). TRACP, which was first identified in human leukocytes, has 2 isoforms TRAP-5a derived from macrophages and dendritic cells and TRACP-5b secreted by osteoclasts. it is believed that TRACP-5b is a useful marker of osteoclast activity, even a marker for osteoclast number, as it is associated with osteoclast differentiation, activation and proliferation. Furthermore, it has the advantage of not being affected by renal dysfunction, nor food intake and has a weak diurnal variability. And this is why it has been used as one of the bone turnover markers in evaluating the efficacy of different anti-resorptive treatments in postmenopausal osteoporosis and in 2ry OP due to rheumatoid arthritis as well as in evaluating its specificity in identification of postmenopausal OP when compared to measurement of more expensive, relatively unavailable bone mineral density (BMD).So far, limited researches are available regarding the TRACP-5b level difference among 1ry OP (postmenopausal women) and 2ry OP (ex. RA, SpA).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Primary osteoprosis patients patients older than 18 years with primary osteoporosis diagnosed by dxa scan . tartrate- resistant acid phosphatase 5b level will be measured. |
Diagnostic Test: Tartrate- resistant Acid Phosphatase marker
marker could be diagnostic for osteoporosis
|
| Rheumatoid arthritis patients patients older than 18 years with primary osteoporosis diagnosed by dxa scan and rhumatoid arthritis. tartrate- resistant acid phosphatase 5b level will be measured. |
Diagnostic Test: Tartrate- resistant Acid Phosphatase marker
marker could be diagnostic for osteoporosis
|
| Ankylosing spondylitis patients patients older than 18 years with primary osteoporosis diagnosed by dxa scan and ankylosing spondylitis. tartrate- resistant acid phosphatase 5b level will be measured. |
Diagnostic Test: Tartrate- resistant Acid Phosphatase marker
marker could be diagnostic for osteoporosis
|
| Control group patients older than 18 years not complaining of any bone disease tartrate- resistant acid phosphatase 5b level will be measured. |
Diagnostic Test: Tartrate- resistant Acid Phosphatase marker
marker could be diagnostic for osteoporosis
|
Outcome Measures
Primary Outcome Measures
- Assessment of the TRACP-5b level in 1ry OP and 2ry OP such as RA and seronegative, that may help in surrogating the use of BMD. [Baseline]
Assessing Tartrate- resistant Acid Phosphatase Marker in primary osteoporosis, rheumatoid arthritis, ankylosing spondylitis and control group that may help in substituting Dxa scan.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with 1ry OP diagnosed by DXA scan .
-
Any RA and SpA patients (older than 18 years old), who fulfill the for mentioned diseases criteria with secondary osteoporosis as diagnosed by DXA scan.
Exclusion Criteria:
-
Patients unwilling to participate in the study.
-
Patients with other autoimmune diseases.
-
Patients depending on Glucocorticoids with in the last 6 month.
-
Patients with other causes of 2ry OP (ex. Endocrinal abnormalities, Gastrointestinal diseases, Renal diseases…..etc.)
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
- Principal Investigator: AMIRA MA MANSOUR,
Study Documents (Full-Text)
None provided.More Information
Publications
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. Review.
- Mederle OA, Balas M, Ioanoviciu SD, Gurban CV, Tudor A, Borza C. Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis. Clin Interv Aging. 2018 Aug 3;13:1383-1389. doi: 10.2147/CIA.S170111. eCollection 2018.
- Mochizuki T, Yano K, Ikari K, Okazaki K. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia. 2021 Sep;7(3):110-114. doi: 10.1016/j.afos.2021.08.001. Epub 2021 Aug 27.
- Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int. 2005 Sep;16(9):1109-16. Epub 2004 Dec 17.
- TRACP-5b in Osteoprosis